Insulin-like Growth Factor (igf) Or Derivative Patents (Class 514/8.5)
-
Publication number: 20130323199Abstract: A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments.Type: ApplicationFiled: February 20, 2012Publication date: December 5, 2013Applicant: Atree, Inc.Inventors: Taro Saku, Yoshihiro Isobe, Takaoki Isobe
-
Publication number: 20130315997Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: ApplicationFiled: April 30, 2013Publication date: November 28, 2013Applicant: CORETHERAPIX, SLUInventor: CORETHERAPIX, SLU
-
Publication number: 20130309304Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Inventor: Bernardo Nadal-Ginard
-
Patent number: 8586070Abstract: The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.Type: GrantFiled: January 24, 2012Date of Patent: November 19, 2013Assignee: SBF Synthetic Bone Factory GmbHInventor: Arne Briest
-
Publication number: 20130302347Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.Type: ApplicationFiled: May 23, 2013Publication date: November 14, 2013Inventors: Adrian Lobito, Wenjun Ouyang, Lino C. Gonzalez, JR.
-
Publication number: 20130287817Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.Type: ApplicationFiled: April 27, 2012Publication date: October 31, 2013Applicant: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Daniel A. Shimko
-
Publication number: 20130288965Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: JOHANNES GERHARDUS MARIA BOLSCHER, ARIE VAN NIEUW AMERONGEN, ENGELMUNDUS CORNELIS IGNATIUS VEERMAN, MENNO JOHANNES OUDHOFF, WILLEM VAN'T HOF, KAMRAN NAZMI, PETRONELLA ADRIANA MARIA VAN DEN KEIJBUS
-
Publication number: 20130288964Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: Johannes Gerhardus Maria Bolscher, Arie van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem van't Hof, Kamran Nazmi, Petronella Adriana Maria van den Keijbus
-
Publication number: 20130281369Abstract: A method for promoting hair growth in a human in need of promoting hair growth. The method includes preparing a composition comprising a therapeutically effective amount of at least three of: a Bone Morphogenetic Protein, Transforming Growth Factor Beta, Platelet Derived Growth Factor, Insulin-like Growth Factor, Basic Fibroblastic Growth Factor and Vascular Endothelial Growth Factor; and administering the composition to the human.Type: ApplicationFiled: April 18, 2012Publication date: October 24, 2013Inventor: Mark Laney
-
Publication number: 20130261055Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 96) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.Type: ApplicationFiled: September 25, 2010Publication date: October 3, 2013Inventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
-
Publication number: 20130259875Abstract: Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.Type: ApplicationFiled: May 10, 2011Publication date: October 3, 2013Applicant: QUESTCOR PHARMACEUTICALS, INC.Inventor: Kathleen C. Somera-Molina
-
Publication number: 20130252888Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.Type: ApplicationFiled: January 16, 2013Publication date: September 26, 2013Applicant: University of Massachusetts Medical SchoolInventor: Zhong Jiang
-
Publication number: 20130243866Abstract: A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in ?-sheet structure dominant silk microsphere structures having about 2 ?m in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. KAPLAN, Xiaoqin WANG
-
Publication number: 20130230598Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: LG LIFE SCIENCES, LTD., INC.Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON
-
Patent number: 8518877Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, such combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.Type: GrantFiled: April 18, 2008Date of Patent: August 27, 2013Assignee: Premacure ABInventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
-
Publication number: 20130195991Abstract: The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.Type: ApplicationFiled: March 25, 2011Publication date: August 1, 2013Applicant: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Minoru Ueda, Yoichi Yamada, Katsumi Ebisawa, Akihito Yamamoto, Kiyoshi Sakai, Kohki Matsubara, Hisashi Hattori, Masahiko Sugiyama, Takanori Inoue
-
Patent number: 8492338Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: May 25, 2012Date of Patent: July 23, 2013Assignee: Biomarin Pharmaceutical Inc.Inventors: Jonathan LeBowitz, Stephen M. Beverley, William S. Sly
-
Patent number: 8492337Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: August 3, 2011Date of Patent: July 23, 2013Assignee: Biomarin Pharmaceutical Inc.Inventors: Jonathan LeBowitz, Stephen M. Beverley
-
Publication number: 20130184206Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.Type: ApplicationFiled: October 23, 2012Publication date: July 18, 2013Applicant: Ligand Pharmaceuticals IncorporatedInventor: Ligand Pharmaceuticals Incorporated
-
Patent number: 8481064Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.Type: GrantFiled: March 1, 2010Date of Patent: July 9, 2013Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130171094Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.Type: ApplicationFiled: January 14, 2011Publication date: July 4, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
-
Publication number: 20130164303Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: ApplicationFiled: November 7, 2011Publication date: June 27, 2013Applicant: Orthogen AGInventors: Peter Wehling, Julio Reinecke
-
Publication number: 20130143810Abstract: The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal.Type: ApplicationFiled: November 26, 2012Publication date: June 6, 2013Inventors: Thierry BURNOUF, Cheng-Yao SU
-
Patent number: 8445434Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.Type: GrantFiled: March 9, 2012Date of Patent: May 21, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Patent number: 8440616Abstract: The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day.Type: GrantFiled: March 12, 2012Date of Patent: May 14, 2013Assignee: Tercica, Inc.Inventor: Gillian Clark
-
Publication number: 20130095060Abstract: The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.Type: ApplicationFiled: April 10, 2012Publication date: April 18, 2013Applicant: National Cheng Kung UniversityInventors: PATRICK C.H. HSIEH, YI-DONG LIN
-
Publication number: 20130071366Abstract: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: Cancer Research Technology LimitedInventors: Andrew Bassim Hassan, Oliver Zaccheo, Stuart Prince
-
Publication number: 20130012435Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: June 26, 2012Publication date: January 10, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
-
Publication number: 20120328557Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.Type: ApplicationFiled: June 23, 2011Publication date: December 27, 2012Applicants: Excel Med, LLC, National Cheng Kung UniversityInventor: Lynn L.H. Huang
-
Publication number: 20120316110Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.Type: ApplicationFiled: March 26, 2012Publication date: December 13, 2012Applicant: Ben-Gurion University of the NegevInventors: Smadar Cohen, Jonathan Leor
-
Publication number: 20120316111Abstract: The present disclosure relates to a method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of one or more of the following compounds prazosin, quinacrine, emetine, apomorphine, and debrisoquine, whereby endogenous BMP-2 up-regulation is stimulated in said subject. The endogenous BMP-2 up-regulation may enhance bone formation and/or cartilage formation.Type: ApplicationFiled: June 8, 2011Publication date: December 13, 2012Applicant: SOUTHWEST RESEARCH INSTITUTEInventor: Jorge G. ROSSINI
-
Publication number: 20120302498Abstract: It is described the preparation of Insulin like peptides, of chimeric Insulin like peptides and of their derivatives by the random combination of their chains A and their chains B and the pharmaceutical application of the obtained products.Type: ApplicationFiled: October 8, 2010Publication date: November 29, 2012Applicant: Chemical & Biopharmaceutical Laboratories of Patras SAInventors: Kleomenis Barlos, Konstantinos Barlos
-
Publication number: 20120263685Abstract: The present invention relates to a composition for preventing or treating cancer, which contains one or more selected from the group consisting of human adult stem cells and their secretory products, and to a method of preventing or treating cancer using the same. Particularly, the invention relates to the use of adult stem cells that exhibit the effect of preventing or treating cancer by activating the immune system. The human adult stem cells of the invention are administered by a simple method such as intravenous injection and are highly valuable as a cell therapeutic agent for treating various cancer (tumor) diseases. Thus, the adult stem cells will be highly useful in anticancer studies.Type: ApplicationFiled: April 7, 2010Publication date: October 18, 2012Applicant: RNL BIO CO., LTDInventors: Jeong Chan RA, Sung Keun KANG, Sang Kyu WOO, Hwa Young YOUN, Hee Woo LEE, Kyoung Won SEO
-
Publication number: 20120266263Abstract: The present invention provides compositions of insulin-like growth factor II (IGF-II) peptides or nucleic acids for the treatment of memory disorders and to enhance memory in subjects in need thereof.Type: ApplicationFiled: October 14, 2010Publication date: October 18, 2012Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventors: Cristina M. Alberini, Dillon Y. Chen
-
Publication number: 20120258160Abstract: Cellulose and sulfated cellulose fibrous meshes exhibiting robust structural and mechanical integrity in water were fabricated using a combination of electrospinning, thermal-mechanical annealing and chemical modifications. The sulfated fibrous mesh exhibited higher retention capacity for human recombinant bone morphogenetic protein-2 than the cellulose mesh, and the retained proteins remained biologically active for at least 7 days. The sulfated fibrous mesh also more readily supported the attachment and osteogenic differentiation of rat bone marrow stromal cells in the absence of osteogenic growth factors. These properties combined make the sulfated cellulose fibrous mesh a promising bone tissue engineering scaffold.Type: ApplicationFiled: April 3, 2012Publication date: October 11, 2012Inventors: Jie Song, Tera Marie Fillion Potts, Artem Kutikov
-
Publication number: 20120244111Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: ApplicationFiled: June 11, 2012Publication date: September 27, 2012Applicant: Stem Cell Therapeutics Corp.Inventors: Samuel WEISS, Emeka ENWERE, Linda ANDERSEN, Christopher GREGG
-
Publication number: 20120237525Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: ApplicationFiled: December 10, 2010Publication date: September 20, 2012Applicant: ORTHOGEN AGInventors: Peter Wehling, Julio Reinecke
-
Publication number: 20120230950Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: May 21, 2012Publication date: September 13, 2012Applicant: Humacyte, Inc.Inventors: Laura Niklason, Yuling Li, Juliana Blum, Shannon Dahl, Geoffrey Erickson, Frank Zeigler
-
Publication number: 20120195861Abstract: Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.Type: ApplicationFiled: January 14, 2011Publication date: August 2, 2012Applicant: The General Hospital CorporationInventors: Jonathan L. Tilly, Joshua Johnson
-
Publication number: 20120195939Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: ApplicationFiled: March 20, 2012Publication date: August 2, 2012Inventor: Bernardo Nadal-Ginard
-
Publication number: 20120189669Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.Type: ApplicationFiled: May 23, 2010Publication date: July 26, 2012Applicant: CARTIHEAL (2009) LTD.Inventors: Nir Altschuler, Razi Vago
-
Patent number: 8227421Abstract: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.Type: GrantFiled: September 17, 2009Date of Patent: July 24, 2012Assignees: University of Miami, The United States of America represented by the Department of Veteran AffairsInventors: Andrew Schally, Jozsef Varga, Marta Zarandi, Ren Zhi Cai
-
Publication number: 20120183630Abstract: The present invention realtes to compositions and methods to improve the microenvironments in and around the wound in an effort to enhance healing. Specifically, the present invention comprises application of tissue and cells culture nutrient media, such as minimum essential media, supplemented with insulin and/or with substances exhibiting insulin-like activity, such as cinnamon or cinnamon extracts including but not limited to MHCP. The media is applied to the wound to stimulate the viable cells in the wound bed and the adjacent cells in the periphery of the wound to proliferate and grow into the wound in order to achieve wound closure.Type: ApplicationFiled: April 12, 2011Publication date: July 19, 2012Inventor: Ella Lindenbaum
-
Publication number: 20120183585Abstract: The various embodiments herein provide a gel based wound dressing comprising a lyophilized powder and a water-based solvent. The lyophilized powder comprises several nanoparticles and water miscible natural or synthetic polymers. The nanoparticles comprises pectin and a wound healing agent or an anti-microbial agent. The anti-microbial agent is nisin. The lyophilized powder and the water-based solvent are kept in two separate sealed packages and are mixed together before applying on a wound. The embodiments herein also provide a method of synthesizing the gel based wound dressing. The nano-particles control a release of the wound healing agent or the antimicrobial agent to a wound.Type: ApplicationFiled: February 25, 2012Publication date: July 19, 2012Inventors: Rassoul Dinarvand, Nasrin Samadi, Azade Taheri Borujeni
-
Publication number: 20120177702Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.Type: ApplicationFiled: May 23, 2010Publication date: July 12, 2012Applicant: CARTIHEAL (2009) LTD.Inventors: Nir Altschuler, Razi Vago
-
Publication number: 20120171257Abstract: Disclosed are methods for producing cell-guiding fibroinductive and angiogenic tissue engineering scaffolds composed of biodegradable and biocompatible natural biopolymers, synthetic polymers and/or their combination, incorporating growth and differentiation factors, growth hormone and chemoattractants, with interconnected pores and channels-containing microarchitecture inducing the regenerative cell migration, adhesion, proliferation and differentiation from the healthy tissues surrounding the periodontal defects, thereby facilitating the functional periodontal tissue regeneration. The methods for the application of the cell-guiding fibroinductive and angiogenic scaffolds in the surgical treatment of periodontal tissue defects resulted from destructive periodontal diseases are also provided.Type: ApplicationFiled: September 12, 2009Publication date: July 5, 2012Inventors: Bülend Inanç, Levent Inanç
-
Patent number: 8207114Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: November 2, 2009Date of Patent: June 26, 2012Assignee: Biomarin Pharmaceutical Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20120148529Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.Type: ApplicationFiled: May 12, 2010Publication date: June 14, 2012Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
-
Publication number: 20120148499Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide or aptamer that specifically binds to the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that specifically bind to neurons or nerves and for compositions thereof.Type: ApplicationFiled: April 15, 2010Publication date: June 14, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Roger Y. Tsien, Quyen T. Nguyen, Michael Whitney
-
Patent number: RE43982Abstract: A method of treating injuries to or diseases of the central nervous system that predominantly effects glia and/or non-cholinergic neuronal cells characterized in that it comprises the step of increasing the active concentration(s) of insulin-like growth factor 1 and/or analogues thereof in the central nervous system of the patient. The present invention also provides therapeutic compositions comprising insulin-like growth factor 1 and/or analogues thereof for administration to a patient at or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.Type: GrantFiled: June 27, 2003Date of Patent: February 5, 2013Assignees: Genentech Inc., Auckland Uniservices LimitedInventors: Peter Gluckman, Karoly Nikolich